DOBUTAMINE-HAMELN 250 MG/20 ML AMPOULE

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Buy It Now

Active ingredient:

DOBUTAMINE HYDROCHLORIDE

Available from:

Hameln Pharmaceuticals GmbH

Dosage:

12.5 Mg/Ml

Pharmaceutical form:

Concentrate for Soln for Inf

Authorization date:

2003-11-04

Summary of Product characteristics

                                PART II
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Dobutamine-hameln 250 mg/20 ml ampoule, concentrate for solution
for infusion.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
1ml of solution contains 12.5mg Dobutamine equivalent to 14mg
Dobutamine HCl. Each 20 ml ampoule contains 
250mg Dobutamine equivalent to 280mg Dobutamine Hydrochloride.
For excipients, see 6.1
3 PHARMACEUTICAL FORM
Concentrate for solution for infusion.
A clear, colourless or almost colourless solution.
4 CLINICAL PARTICULARS 
4.1 THERAPEUTIC INDICATIONS
Dobutamine is indicated for adults who
require inotropic support in the treatment of low output cardiac failure 
associated with myocardial infarction, open heart surgery
or cardiomyopathies. Dobutamine is also indicated for 
adults with cardiogenic or septic shock who are not severely
hypotensive. Dobutamine can increase or maintain 
cardiac output during positive end expiratory
pressure (PEEP) ventilation.
Dobutamine may also be used for cardiac stress testing in
case where exercise stress testing is not feasible or 
inadequate.
4.2 POSOLOGY AND METHOD OF ADMINSTRATION
Due to its short half-life dobutamine has to be administered by
continuous intravenous infusion.
Dobutamine Hameln 12.5 mg/ml may be diluted if wanted.
Diluents may be 5 % glucose solution, 0.9 % sodium 
chloride solution, Ringer-lactate or 0.45 % sodium chloride in 5
% glucose solution.
Note: Dobutamine Hameln 12.5 mg/ml may not be mixed with 5
% sodium bicarbonate solution or any other strong 
alkaline solution. Due to the risk of incompatibility
Dobutamine Hameln 12.5 mg/ml Amp. 20 ml is not recommended 
to be mixed in the same infusion as other medical substances.
Dobutamine Hameln 12.5 mg/ml should not be used in
solutions for intravenous infusion containing both sodium 
metabisulphite and ethanol. Sulphite is a very
reactive subs
                                
                                Read the complete document